Quest Diagnostics Jumps After Q4 Beat, Big Buyback
Quest Diagnostics (DGX) surged after reporting a stronger-than-expected Q4 with revenue of $2.81B and adjusted EPS of $2.42, while announcing a 7.5% dividend increase and $1B additional share buyback authorization. Analysts raised price targets and the stock briefly hit a 52-week high, signaling investor confidence tied to durable diagnostic demand and robust capital returns.
